Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

ILX-651 enters new phase II study in melanoma

Oct. 10, 2003

Novel heparanase inhibitors and their use as antitumor agents described in recent patent

Oct. 9, 2003

News-breaking molecule: the first and only reported potent inhibitor of human asparagine synthase

Oct. 9, 2003

Antitumor efficacy and safety of arzoxifene in advanced endometrial cancer

Oct. 8, 2003

Sequential combination therapy reported effective in advanced follicular lymphoma

Oct. 8, 2003

Arius and PDL enter cancer antibody development partnership

Oct. 6, 2003

Rolling NDA submission continues for RSR-13

Oct. 6, 2003

Bayer presents two novel series of antitumor agents in recent patent literature

Oct. 6, 2003

Abraxane exceeds primary efficacy objective in phase III trial

Oct. 6, 2003

Phase III protocol for STR in multiple myeloma agreed under SPA

Oct. 3, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...